Research & Regulatory News

What the Systematic Reviews Say About Children and Adolescents

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Two systematic reviews with meta-analysis published in 2025 assessed GLP-1 receptor agonists in children and adolescents: Kotecha and colleagues in JAMA Pediatrics and Sedenho-Prado and colleagues in the International Journal of Obesity.

Key facts

Kotecha 2025
JAMA Pediatr, 1 December (PMID 40952752)
Sedenho-Prado 2025
Int J Obes, August (PMID 40269110)
Design
Systematic review and meta-analysis
Populations
Children and adolescents
Landmark trial
STEP TEENS, NEJM 2022
Still absent
Long-term follow-up data

Why review-level evidence appeared when it did

Systematic reviews require a body of primary studies to review. Two independent meta-analyses appearing in 2025 indicates enough paediatric trials had accumulated to make pooling worthwhile, which is itself a statement about how quickly this field moved after the adult approvals.

What a meta-analysis adds over individual trials

Precision and breadth. Pooling across studies narrows confidence intervals and can detect adverse events too infrequent to appear reliably in any single trial. It also assesses the quality of the underlying evidence, which individual papers do not do for themselves.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What it cannot add

Duration. A meta-analysis of 68-week trials produces a more precise estimate of what happens over 68 weeks; it cannot say anything about year five. Pooling more short studies never becomes a long study, and that is the specific limitation that matters most for a population who may be treated for decades.

The two reviews cover different ground

Kotecha and colleagues addressed efficacy and safety in children and adolescents with obesity or type 2 diabetes in JAMA Pediatrics. Sedenho-Prado and colleagues addressed metabolic outcomes and safety in children and adolescents with obesity in the International Journal of Obesity. Overlapping but distinct questions, published independently in the same year.

Where the underlying trials sit

STEP TEENS remains the landmark, with 201 randomised adolescents over 68 weeks. Tirzepatide's adolescent Phase 3, NCT06075667, reached primary completion in June 2026 with 160 participants aged 12 to 17. The evidence base is real and it is young.

The boundary this site maintains

Everything described concerns licensed medicines and registered trials in paediatric populations, conducted under clinical supervision with ethics approval and specialist oversight. Nothing supplied here is any of those compounds, is an alternative to them, or has any place in the care of a child.

Frequently asked questions

Is there systematic review evidence in children?

Yes. Two independent systematic reviews with meta-analysis were published in 2025, in JAMA Pediatrics and the International Journal of Obesity.

Does pooling trials tell us about long-term effects?

No. Pooling 68-week trials gives a more precise estimate of 68 weeks. It never becomes a long-term study.

What is the landmark paediatric trial?

STEP TEENS, published in NEJM in December 2022, with 201 randomised adolescents over 68 weeks.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.